Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Verrica Pharmaceuticals Inc.

Get SEC filing alerts via email and in your feed for Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals develops dermatology treatments, including FDA-approved YCANTH (VP-102) for molluscum contagiosum, a contagious skin disease. The company focuses on clinician-administered therapies for high unmet needs, with pipeline products targeting common warts and dermatologic cancers like basal cell carcinoma. Its business model emphasizes innovative formulations, strategic licensing, and commercialization through specialized sales, targeting healthcare providers and patients worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Verrica Pharmaceuticals Inc.

1
1
Verrica Pharmaceuticals Inc. Verrica Pharmaceuticals Reports $5.0 Million Revenue in Q1 2026, Net Loss of $9.7 Million

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Verrica Pharmaceuticals Inc. Verrica Pharmaceuticals Reports Revenue Growth and Decreased Losses for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Verrica Pharmaceuticals Inc. Verrica Pharmaceuticals Reports $14.3M Revenue and Improved Financial Performance for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Verrica Pharmaceuticals Inc. Verrica Pharmaceuticals Reports $12.7M Revenue and $204K Net Income in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Verrica Pharmaceuticals Inc. Verrica Pharmaceuticals Reports Q1 2025 Financial Results with Revenue Decline and Improved Losses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Verrica Pharmaceuticals Inc. Verrica Pharmaceuticals Reports $76.6 Million Net Loss for 2024, Increased Product Revenue

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Verrica Pharmaceuticals Inc. Verrica Pharmaceuticals Reports Mixed Financial Results, Launches Commercial Operations for YCANTH

Via official filing (AI summary) | over 1 year ago | 0 comments